<DOC>
	<DOC>NCT01247194</DOC>
	<brief_summary>The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.</brief_summary>
	<brief_title>A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Eligibility Criteria: Male or female, between 18 and 65 years of age (female patients must be surgically sterile or 2 years postmenopausal and are required to take a pregnancy test) Body Mass Index (BMI) 18 32 kg/m2 Chronically infected with hepatitis C genotype1 virus Serum HCV RNA &gt; 5 log10 IU/mL No previous treatment with interferon, peginterferon, ribavirin or any investigational HCV antiviral agents No history of signs or symptoms of decompensated liver disease No known history of cirrhosis No coinfection with HBV, HIV1, HIV2 No history of any medical condition that may interfere with absorption, distribution or elimination of study drug or with the clinical and laboratory assessments in this study No history of alcohol abuse, or illicit drug use within 2 years prior to Screen, or enrollment in a methadone maintenance program (unless he/she has been enrolled in the methadone program for at least 3 months with good compliance, stable psychosocial circumstances, and no known current risks for recidivism)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>NS5A</keyword>
	<keyword>HCV RNA</keyword>
</DOC>